Name Targets   Structure Type of Structure /Function /Side effects Company
/Phase
SAR-302503/ TG-101348 JAK2/RET Aminopyrimidines;
Drug of Ph chromosome-negative myeloproliferative neoplasms [44,45]; Nausea, diarrhoea, anaemia [46]
Sanofi-
Aventis
Phase II
LY-2784544 JAK2 Imidazolepyrazole;
Polycythaemia vera, essential-
Thrombocythaemia;
Tumour lysis syndrome [47]
Lilly
Phase II
BMS-911453 JAK2 Pyrroleimidazopyridine;
Inhibited CD34 + from bone marrow fibrosis;
Not determined [48]
BRistol-
MyeRsSquibb
Phase I
XL-019 JAK2 Pyrrole amides;
Myeloproliferative disorders [49];
Phenomenon of central and peripheral neuropathy
Exelixis
PhaseI (termination)
AG-490 JAK2 Styrene amine;
Specific JAK2 antagonist [50];
Tools compound
No reports of clinical studies
Table 3: Presentation of other selective JAK2 inhibitors.